tuberculosis tuberculose
Conditions
Interventions
No new medicinal product or intervention is administered. The study only investigates rifampicin concentrations measured in saliva, finger-prick samples and venous blood samples. These methods of obta
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: children and adolescents aged 0-18 yearsCurrently receiving oral rifampicin for > 7 days (steady state) for tuberculosis, or > 14 days if undergoing treatment for contagious tuberculosis, at which point participants are considered non-contagious.Written informed consent obtained as follows: For adolescents aged 16-18 years: written informed consent from the adolescentFor children aged 12-16 years: written informed consent from both the child and their parents or guardiansFor children < 12 years written informed consent from both parents or from the legal guardian.
Exclusion criteria
Exclusion criteria: A potential participant who meets any of the following criteria will be excluded from participation of the studySevere comorbid illnessAcute viral hepatitis Clotting disorders Severe skin diseases on places where dried blood spots and venous samples are collected
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We are investigating whether the amount of the medicine rifampicin measured in a standard blood sample taken from a vein is the same as the amount measured using a finger-prick sample or saliva. This study is conducted in children and young people aged 0-18 years with tuberculosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| We also examine how children, young people, parents and healthcare providers experience the different methods to determine which method is most practical and comfortable. | — |
Countries
Netherlands
Contacts
Public ContactA.R. Verhage Verhage
Universitair Medisch Centrum Groningen
Outcome results
None listed